Navigation Links
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Date:10/16/2007

KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.

"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."

Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.

"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."

Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.

Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 2008.

For more information, log on to http://www.pvct.com.


'/>"/>
SOURCE Provectus Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
2. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
10. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/23/2017)... Care, based in St. Joseph, Missouri , has selected AccuReg to ... located in 22 cities, and its flagship St. Joseph Medical Center. Mosaic ... health care to its patients, including the insurance, billing and collections processes. ... ... Care St. Joseph Medical Center ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of Serenity ... MD. Judy says, “I am passionate about sharing Reiki as a holistic, complementary ... and challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys ...
Breaking Medicine News(10 mins):